Sugi Predict

Sugi Predict / Compounds / SCHEMBL29353000

SCHEMBL29353000

SCHEMBL29353000

CC(C)(C)OC(=O)Nc1ccccc1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 10/20 0.52
▸ HDAC3 O15379 8/20 0.50
▸ HDAC2 Q92769 7/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HDAC10 Q969S8 4/20 0.49
▸ HDAC6 Q9UBN7 4/20 0.49
▸ HDAC4 P56524 3/20 0.49
▸ HDAC7 Q8WUI4 3/20 0.49
▸ HDAC11 Q96DB2 3/20 0.49
▸ HDAC8 Q9BY41 3/20 0.49
▸ HDAC9 Q9UKV0 3/20 0.49
▸ HDAC5 Q9UQL6 3/20 0.49
▸ BRD9 Q9H8M2 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ NCOR2 Q9Y618 3/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.47
▸ PTGS1 P23219 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL211033 1.00 HDAC1 (0.52) HDAC1HDAC3HDAC2MAPK1HDAC10
Pyridine SCHEMBL28213555 0.90 HDAC1 (0.48) HDAC1HDAC3HDAC2MAPK1HDAC10
SCHEMBL3783723 0.87 BRD9 (0.47) HDAC1HDAC3HDAC2HDAC10HDAC6
SCHEMBL2880191 0.87 LMNA (0.54) BRD9LMNAPOLBRXFP1NPC1
O-Tolylamine SCHEMBL19586028 0.86 NPC1 (0.49) HDAC1BRD9LMNAPOLBRXFP1
SCHEMBL12598517 0.85 BRD9 (0.45) HDAC1HDAC3HDAC2HDAC10HDAC6
SCHEMBL1172444 0.85 RXFP1 (0.44) HDAC1HDAC3HDAC2HDAC10HDAC6
SCHEMBL38664167 0.85 HDAC1 (0.47) HDAC1HDAC3HDAC2MAPK1HDAC10
SCHEMBL3786531 0.85 BRD9 (0.51) HDAC1HDAC3HDAC2MAPK1HDAC10
SCHEMBL3788603 0.85 HSP90AA1 (0.46) HDAC1HDAC3HDAC2HDAC10HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119569678-A Thionitrous near-infrared bioluminescence probe and preparation method and application thereof 徐州医科大学 2025-03-07 — — CN claimed
CN-117603123-A Novel indole HDAC6 small molecule inhibitor, preparation method and application 郑州大学 2024-02-27 — — CN claimed
CN-116947763-A 2-mercapto-5-cyano-6-aryl pyrimidine heterocyclic compound, preparation method and application 郑州大学 2023-10-27 — — CN claimed
CN-113461636-B Benzothiazole-containing phenylalanine derivative and preparation method and application thereof 山东大学 2023-08-08 — — CN claimed
CN-114773321-B Benzimidazole derivative and preparation method and application thereof 重庆文理学院 2023-07-11 — — CN claimed
CN-114890947-A Aromatic heterocyclic compound containing quinoline structural unit and preparation method and application thereof 郑州大学 2022-08-12 — — CN claimed
CN-114773321-A Benzimidazole derivative and preparation method and application thereof 重庆文理学院 2022-07-22 — — CN claimed
CN-113603895-B Preparation method of chitosan-graphene oxide hybrid material 南京工业大学 2022-03-29 — — CN claimed
US-12637436-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2026-05-26 — — US disclosed
EP-4741395-A1 NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Omniamed Co. Ltd (KR) 2026-05-13 — — EP disclosed
EP-4735046-A1 BIOCONJUGATION SYSTEMS AND USES THEREOF Université de Tours (FR) 2026-05-06 — — EP disclosed
US-20260071223-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE ARROWHEAD PHARMACEUTICALS INC (US) 2026-03-12 — — US disclosed
US-20260014174-A1 DUAL INHIBITORS FOR HDAC3 AND HIV-1 PR PURDUE RESEARCH FOUNDATION (US) 2026-01-15 — — US disclosed
EP-4646213-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE Arrowhead Pharmaceuticals, Inc. (US) 2025-11-12 — — EP disclosed
EP-3986411-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE Dana-Farber Cancer Institute, Inc. (US) 2022-04-27 — — EP disclosed
CN-114394978-A Nitric oxide light-activated fluorescent probe and preparation method and application thereof 徐州医科大学 2022-04-26 — — CN disclosed
CN-113603895-B Preparation method of chitosan-graphene oxide hybrid material 南京工业大学 2022-03-29 — — CN disclosed
EP-3154954-B1 METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF SANFORD BURNHAM MED RES INST (US) 2022-02-09 — — EP disclosed
EP-3941900-A1 NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 Deutsches Krebsforschungszentrum (DE) 2022-01-26 — — EP disclosed
US-11230524-B2 Myocyte enhancer factor 2 (MEF2) modulators STANDARD LLC (US) 2022-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230524-B2 Myocyte enhancer factor 2 (MEF2) modulators MEF2D, MYLK2, TNNT2 HDAC1 77/4885HDAC3 133/4885HDAC2 27/4885
US-20260014174-A1 DUAL INHIBITORS FOR HDAC3 AND HIV-1 PR HDAC3, HDAC1, HDAC11 HDAC1 2/4885HDAC3 1/4885HDAC2 4/4885
US-20260071223-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE FABP4, PLIN1, PLIN3 HDAC1 1191/4885HDAC3 773/4885HDAC2 2405/4885
US-12637436-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof GRM3, GRM2, GRM1 HDAC1 632/4885HDAC3 292/4885HDAC2 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.